Amethopterin

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561838

CAS#: 60388-53-6

Description: Amethopterin is a chemotherapy agent and immune system suppressant. It can treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.


Chemical Structure

img
Amethopterin
CAS# 60388-53-6

Theoretical Analysis

Hodoodo Cat#: H561838
Name: Amethopterin
CAS#: 60388-53-6
Chemical Formula: C20H22N8O5
Exact Mass: 454.17
Molecular Weight: 454.440
Elemental Analysis: C, 52.86; H, 4.88; N, 24.66; O, 17.60

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Amethopterin; DL-Amethopterin;

IUPAC/Chemical Name: 2-[[4-[(2,4-Diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid

InChi Key: FBOZXECLQNJBKD-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

SMILES Code: O=C(O)C(NC(C1=CC=C(N(CC2=NC3=C(N)N=C(N)N=C3N=C2)C)C=C1)=O)CCC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 454.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Suzuki R. NK/T Cell Lymphoma: Updates in Therapy. Curr Hematol Malig Rep. 2018 Jan 24. doi: 10.1007/s11899-018-0430-5. [Epub ahead of print] Review. PubMed PMID: 29368155.

2: McDaniel BL, Bentley ML. The role of medications and their management in acute kidney injury. Integr Pharm Res Pract. 2015 May 18;4:21-29. doi: 10.2147/IPRP.S52930. eCollection 2015. Review. PubMed PMID: 29354517; PubMed Central PMCID: PMC5741024.

3: Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK476185/ PubMed PMID: 29356468.

4: Pradère B, Thibault C, Vetterlein MW, Leow JJ, Peyronnet B, Rouprêt M, Seisen T. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. Transl Androl Urol. 2017 Dec;6(6):1049-1059. doi: 10.21037/tau.2017.09.12. Review. PubMed PMID: 29354492; PubMed Central PMCID: PMC5760386.

5: Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Shachter J, Shapira-Frommer R, Markel G. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018 Jan 13. pii: S1568-9972(18)30010-7. doi: 10.1016/j.autrev.2018.01.003. [Epub ahead of print] Review. PubMed PMID: 29341936.

6: Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci. 2018 Jan 16. doi: 10.17305/bjbms.2018.2792. [Epub ahead of print] Review. PubMed PMID: 29338679.

7: Millan NC, Pastrana A, Guitter MR, Zubizarreta PA, Monges MS, Felice MS. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia. Leuk Res. 2018 Jan 2;65:86-93. doi: 10.1016/j.leukres.2017.12.010. [Epub ahead of print] Review. PubMed PMID: 29328996.

8: Yeganeh MH, Kheir MM, Shahi A, Parvizi J. Rheumatoid Arthritis, Disease Modifying Agents, and Periprosthetic Joint Infection: What Does a Joint Surgeon Need to Know? J Arthroplasty. 2017 Nov 23. pii: S0883-5403(17)31036-7. doi: 10.1016/j.arth.2017.11.031. [Epub ahead of print] Review. PubMed PMID: 29325724.

9: Lauvrak V, Norderhaug IN. Infection Preventive Interventions in Primary Total Hip Replacements [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2011 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK464841/ PubMed PMID: 29320057.

10: Arentz-Hansen H, Palm Ø, Natvig Norderhaug I, Klemp Gjertsen M, Nordvåg BY. Tumor Necrosis Factor (TNF) Inhibitors for Rheumatic Diseases (Part 2): A Systematic Review of Data From Registries and Safety Databases [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2007 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK464738/ PubMed PMID: 29319954.

11: Taddio A, Ferrara G, Insalaco A, Pardeo M, Gregori M, Finetti M, Pastore S, Tommasini A, Ventura A, Gattorno M. Dealing with Chronic Non-Bacterial Osteomyelitis: a practical approach. Pediatr Rheumatol Online J. 2017 Dec 29;15(1):87. doi: 10.1186/s12969-017-0216-7. Review. PubMed PMID: 29287595; PubMed Central PMCID: PMC5747935.

12: Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2. Review. PubMed PMID: 29271481.

13: Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Am J Clin Dermatol. 2017 Dec 19. doi: 10.1007/s40257-017-0337-2. [Epub ahead of print] Review. PubMed PMID: 29260411.

14: Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. 2017 Dec 14. doi: 10.1007/s10238-017-0479-9. [Epub ahead of print] Review. PubMed PMID: 29243035.

15: Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, Shapiro J. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018 Jan;78(1):15-24. doi: 10.1016/j.jaad.2017.04.1142. Review. PubMed PMID: 29241773.

16: Schneider-Burrus S, Arpa E, Kors C, Stavermann T, Sabat R, Kokolakis G. [Drug therapy of acne inversa]. Hautarzt. 2018 Jan;69(1):58-63. doi: 10.1007/s00105-017-4094-1. Review. German. PubMed PMID: 29234829.

17: Silva MF, Ribeiro C, Gonçalves VMF, Tiritan ME, Lima Á. Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review. Biomed Chromatogr. 2017 Dec 11. doi: 10.1002/bmc.4159. [Epub ahead of print] Review. PubMed PMID: 29226354.

18: Savage KJ. Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):578-586. doi: 10.1182/asheducation-2017.1.578. Review. PubMed PMID: 29222307.

19: Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):565-577. doi: 10.1182/asheducation-2017.1.565. Review. PubMed PMID: 29222306.

20: Hough R, Vora A. Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment). Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):251-258. doi: 10.1182/asheducation-2017.1.251. Review. PubMed PMID: 29222263.